BENEFITS Triple receptor activation studied for simultaneous GLP-1, GIP, and glucagon engagement Metabolic research explored in Phase 2 clinical trials with notable body-composition results Glucagon component linked to thermogenesis and energy-expenditure pathways Next-generation compound investigated as an advancement over dual-agonist approaches Comparative pharmacology assessed alongside mono- and dual-agonists in research settings WHAT RESEARCHERS LOOK AT Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors Additive effects of glucagon-receptor activation on energy expenditure Dose-response and tolerability profiling from clinical-trial data Comparative outcomes vs tirzepatide and semaglutide Pharmacokinetic profiling and receptor selectivity QUICK SPECS Form: Lyophilized peptide powder Net per vial: 10 mg Purity: 99% (HPLC verified) Identity: MS-verified (per COA) Storage: 28C, protect from light and moisture Reconstitution: Use bacteriostatic water (sold separately) IDENTITY BASICS CAS: 2381089-83-2 Classification: Triple GLP-1/GIP/glucagon receptor agonist WHY CHOOSE DURHAM PEPTIDES FOR RETATRUTIDE

Its vital for members to verify the availability by contacting local Costco pharmacies listed under the CMPP since participating pharmacies are subject to change without notice
Treatment with tesamorelin resulted in an increase from baseline in mean lean body mass of 1.3 kg in Study 1 and of 1.2 kg in Study 2, respectively (compared with a decrease of 0.2 kg in Study 1 and of 0.03 kg in Study 2, respectively, in patients receiving placebo)
For branded Ozempic, that also means 0.25 mg weekly
Additionally, it produces lighter pheomelanin instead of the darker eumelanin